Barclays
PEAR

Barclays’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Barclays’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,820
Closed -$9.13K – 5331
2023
Q1 		$9.13K Buy
35,820
+17,420
+95% +$15.7K ﹤0.01% 4759
2022
Q4 		$21.7K Buy
18,400
+15,495
+533% +$32.6K ﹤0.01% 4791
2022
Q3 		$6K Buy
+2,905
New +$4.93K ﹤0.01% 4486

Barclays's PEAR Position: Q2 2023 in Review

Barclays sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 35,820 shares — an estimated $9.13K sold.

Barclays first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $21.7K in Q4 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

  • Barclays reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 35,820 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $9.13K.
  • Barclays first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
  • Barclays's Pear Therapeutics, Inc. Class A Common Stock position peaked at $21.7K in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.